JonesTrading is an equity broker and capital market company that provides services including investment banking, electronic trading, and research. Self-described as bridging the gap between issuers and institutional investors.

JonesTrading

JonesTrading | 4,604 followers on LinkedIn. Quietly Moving Mountains | JonesTrading is one of the oldest and largest executing equity trading firms in the U.S. and is a worldwide leader in equity block trading. Since 1975, the sole focus of JonesTrading has been creating liquidity for institutional and corporate clients on an unconflicted basis. The ability to provide a secure, trusted platform connecting a diverse group of market players enables the firm to unlock liquidity, providing best-quality execution for larger and more complex trades.

Mitchell Tangy

Senior Software Engineer at Jones Trading Institutional Services LLC

Glenn Petersen

Managing Director - Global Head Electronic Trading at JonesTrading

Troy Draizen

Co-Head of Prime Services

Mark McGoldrick

Jones is pleased to have served as a financial advisor on KalVista Pharmaceuticals, Inc.'s (NasdaqGM:KALV) $55 million follow-on offering. For any inquiries related to this transaction, please contact our Equity Capital Markets group at ECM@jonestrading.com Read More: https://lnkd.in/eCv6cHt5

With Election Day tomorrow, Jones is excited to share the “Election Edition” of our Healthcare Pulse monthly newsletter. In this special edition, you will find a comprehensive analysis of each presidential election since 2004 including: key issues, major healthcare themes, polling trends, market reactions, and more. While no election is the same, we believe this detailed look at our past helps inform a better understanding of the present and provides insight into the key trends we see today. Please reach out to your Jones representative for more information or a copy of the newsletter.

Jones is pleased to have served as sole book-running manager on CalciMedica, Inc.'s (NasdaqCM:CALC) $10.2 million follow-on offering. For any inquiries related to this transaction, please contact our Equity Capital Markets group at ECM@jonestrading.com Read More: https://lnkd.in/eu6wDXEU

Join JonesResearch for our Virtual Genetic Medicine Day on November 25th, 2024 Connect with industry pioneers and thought leaders through expert panels and intimate fireside chats exploring the future of genetic medicine. Featured Participants: - Management teams from leading public companies covered by JonesResearch, including EDIT, NTLA, PRME, DTIL, WVE, KRRO, and RGLS - Executive leadership from emerging innovators such as Ensoma and iECURE If you are interested in gaining valuable insights into the evolving genetic medicine landscape, please email healthcareevents@jonestrading.com

Jones is pleased to have served as an underwriter on EyePoint Pharmaceuticals, Inc.'s (NasdaqGM:EYPT) $140 million follow-on offering. For any inquiries related to this transaction, please contact our Equity Capital Markets group at ECM@jonestrading.com Read More: https://lnkd.in/edtVixwN

JonesPrime won "Best Prime Broker - Trading Capabilities" at the 2024 Hedgeweek Awards. We appreciate the recognition.

JonesResearch will be hosting a virtual KOL event with Dr. Marijana Tadic, MD, PhD, Associate Professor, Cardiology at the Charité in Berlin, Germany. The call will take place Tuesday, October 22nd, at 1:00 PM ET to discuss recent data from Wave Life Sciences' (NasdaqGM:WVE) upcoming DMD catalysts, key clinical outcomes in DMD, and the European regulatory perspective on DMD endpoints. Please use the following link for registration: https://lnkd.in/eaJdt9qv

We are pleased to announce that Western Asset Mortgage Opportunity Fund Inc. (NYSE:DMO) entered into a sales agreement relating to the shares of the Company’s common stock offered from time to time in sales deemed to be “at the market offerings.” Jones is the Sole Sales Agent for this offering. For any inquiries related to this transaction, please contact our Equity Capital Markets group at ECM@jonestrading.com Read More: https://lnkd.in/eBmUgFW7

Jones is pleased to have served as an underwriter on Crinetics Pharmaceuticals, Inc.'s (NasdaqGS:CRNX) $500 million follow-on offering. For any inquiries related to this transaction, please contact our Equity Capital Markets group at ECM@jonestrading.com Read More: https://lnkd.in/ePFPvNfC

We are pleased to welcome Stephen Glagola , who joins Jones as a Senior Research Analyst covering Emerging Technology. Stephen's addition continues Jones' firmwide expansion in growth verticals. Mr. Glagola brings over a decade of experience covering digital infrastructure, media and entertainment.

JONE

COM:JONESTRADING

JonesTrading